CI
← Investigator Score

Jinming Yu, Ph.D, M.D

Shandong Cancer Hospital and Institute

Emerging Leaders
not ranked
Current Leaders
#2649 pts
All-Time Leaders
#94821 pts

Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2011. 11 trials as lead/chair. How it works →

Trials led — by scientific impact

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
Phase 3RecruitingAstraZeneca
12
impact
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy: a Multicenter Randomized Controlled Phase III Clinical Trial
Phase 3RecruitingShandong Cancer Hospital and Institute
4
impact
SHR-1316 Plus Chemotherapy and Sequential Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): a Phase II Trial
Phase 2ActiveShandong Cancer Hospital and Institute
1
impact
A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
Phase 3UnknownShandong Cancer Hospital and Institute
1
impact
A Perspective Random Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma
Phase 4CompletedShandong Cancer Hospital and Institute
1
impact
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Failed or Intolerance to Standard First-line Therapy
Phase 2RecruitingShanghai Henlius Biotech
0
impact
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Gynecological Malignant Tumors Failed or Intolerance to Standard First-Line Therapy
Phase 2RecruitingShanghai Henlius Biotech
0
impact
Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI
Phase 3UnknownShandong Cancer Hospital and Institute
0
impact
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy
Phase 3RecruitingAkeso
0
impact
A Multi-cohort, Open-label, Multi-center Exploratory Study of Efbemalenograstim Alfa Injection for Preventing Absolute Neutrophil Count (ANC) Reduction in Solid Tumor Patients Undergoing Immune-chemotherapy Regimen.
N/ANot Yet RecruitingShandong Cancer Hospital and Institute
0
impact
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Disitamab Vedotin Intravenously Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression Phase 1 Study
Phase 1RecruitingRemeGen Co., Ltd.
0
impact
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
N/ARecruitingJinming Yu
0
impact
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of Serplulimab or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Phase 3ActiveShanghai Henlius Biotech
0
impact
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
N/ACompletedVarian, a Siemens Healthineers Company
0
impact
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Refractory Primary Brain Tumors With BRAF Mutation
Phase 2UnknownShanghai Henlius Biotech
0
impact
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
Phase 2UnknownShandong Cancer Hospital and Institute
0
impact
Director of Shandong Cancer Hospital and Institute
Phase 2UnknownShandong Cancer Hospital and Institute
0
impact
Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
N/AUnknownShandong Cancer Hospital and Institute
0
impact
A Perspective Trial of Sodium Glycididazole Combined With Concurrent Chemoradiotherapy for Locally Recurrent Squamous Cell Esophageal Carcinoma
Phase 4TerminatedShandong Cancer Hospital and Institute
0
impact
A Perspective Trial of Sodium Glycididazole Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma
Phase 4TerminatedShandong Cancer Hospital and Institute
0
impact
A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer
Phase 4UnknownShandong Cancer Hospital and InstituteStudy Chair
0
impact
An Open-label, Single Arm Study to Explore Whether Potential Image Biomarkers Correlate With Efficacy of Bevacizumab Combined With Conventional Therapy in Newly Diagnosed Glioblastoma
N/AUnknownShandong Cancer Hospital and InstituteStudy Chair
0
impact
A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Erlotinib Versus Etoposide Plus Cisplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of Epidermal Growth Factor Receptor (EGFR) in Exon 19 or 21
Phase 2UnknownJinming YuStudy Chair
0
impact